OncoCyte Corporation (OCX)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of OncoCyte Corporation (OCX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of OncoCyte Corporation (“OncoCyte” or the “Company”) (NASDAQ: OCX. The investigation concerns whether OncoCyte and certain of its officers and/or directors have violated federal securities laws.

 

On June 26, 2019, OncoCyte issued a press release announcing that “the Company will require additional time to complete its ongoing CLIA Validation study of DetermaVu™, its liquid biopsy test for lung cancer.”  On this news, OncoCyte’s stock price fell $1.47 per share, or 36.84%, to close at $2.52 per share on June 26, 2019.

 

If you are aware of any facts relating to this investigation, or purchased OncoCyte shares, you can learn more about the investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484

 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2019 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.